Approximately 30% of patients with acute myeloid leukemia (AML) have an internal tandem duplication (ITD) or tyrosine kinase domain (TKD)-activating mutation in the fms-like tyrosine kinase 3 gene (FLT3). This evidence concerns the gene FLT3 and acute myeloid leukemia.